We're building a better ClinicalTrials.gov. Check it out and tell us what you think!
Try the New Site
We're building a modernized ClinicalTrials.gov! Visit Beta.ClinicalTrials.gov to try the new functionality.
ClinicalTrials.gov Menu
Trial record 2 of 4 for:    VANISH Vein

Efficacy and Safety Study of Polidocanol Injectable Foam for the Treatment of Saphenofemoral Junction (SFJ) Incompetence (VANISH-1)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT01072877
Recruitment Status : Completed
First Posted : February 22, 2010
Results First Posted : May 16, 2014
Last Update Posted : April 21, 2021
Information provided by (Responsible Party):
Boston Scientific Corporation

Brief Summary:
Varicose veins are enlarged, noticeably bulging veins, which commonly occur in the legs and may cause discomfort. In this study, patients with varicose veins in the legs will be participating. The purpose of this research study is to evaluate the safety and effectiveness of three different concentrations of an investigational drug, polidocanol injectable foam compared to vehicle (inactive solution) in treating the symptoms and appearance of varicose veins.

Condition or disease Intervention/treatment Phase
Varicose Veins Drug: Polidocanol injectable foam (PEM) Drug: Placebo Vehicle Phase 3

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 279 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double (Participant, Outcomes Assessor)
Primary Purpose: Treatment
Official Title: A Randomized, Blinded, Multicenter Study to Evaluate the Efficacy and Safety of Polidocanol Injectable Foam 0.5%, 1.0%, or 2.0% Compared to Vehicle for the Treatment of Saphenofemoral Junction (SFJ) Incompetence
Study Start Date : December 2010
Actual Primary Completion Date : December 2011
Actual Study Completion Date : November 2012

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Varicose Veins
Drug Information available for: Polidocanol

Arm Intervention/treatment
Experimental: Polidocanol injectable foam 0.125%
Polidocanol injectable foam 0.125%
Drug: Polidocanol injectable foam (PEM)
Injection of Polidocanol injectable foam

Experimental: Polidocanol injectable foam 0.5%
Polidocanol injectable foam 0.5%
Drug: Polidocanol injectable foam (PEM)
Injection of Polidocanol injectable foam

Experimental: Polidocanol injectable foam 1.0%
Polidocanol injectable foam 1.0%
Drug: Polidocanol injectable foam (PEM)
Injection of Polidocanol injectable foam

Experimental: Polidocanol injectable foam 2.0%
Polidocanol injectable foam 2.0%
Drug: Polidocanol injectable foam (PEM)
Injection of Polidocanol injectable foam

Placebo Comparator: Vehicle
Injection of vehicle comparator
Drug: Placebo Vehicle
Placebo vehicle

Primary Outcome Measures :
  1. Change in Patient-reported Symptoms of Varicose Veins (VVSymQ Score) [ Time Frame: Week 8 ]

    The 9 varicose vein symptoms were to be assessed and graded on a 6-point (i.e., 0-5) duration scale and an 11-point (i.e., 0-10) intensity scale, and the patient's level of activity for that day was to be assessed and graded on the 6-point (i.e., 0-5) duration scale. The 9 varicose vein symptoms assessed using the e-diary were derived from the first question of the modified Venous Insufficiency Epidemiologic and Economic Study-Quality of Life/Symptoms (VEINES-QOL/Sym) instrument. The VVSymQ is a subset of 5 VEINESQOL/ Sym items that have been determined in earlier studies to be most important to patients (heaviness, achiness, swelling, throbbing, and itching).

    The daily VVSymQ score is the sum of the duration scores for these 5 symptoms (scores range from 0 to 25, with the lower end of the range being an indicator of less symptom intensity, and the higher end being an indicator of higher intensity).

    At Visit 2/baseline, Week 8, scores were calculated

Secondary Outcome Measures :
  1. Change From Baseline to 8 Weeks in Appearance as Rated by Patient (PA-V3) [ Time Frame: 8 weeks ]
    The Patient Self-assessment of Visible Varicose Veins (PA-V3) instrument is a 5-point scale used by patients to evaluate the appearance of their visible varicose veins. On this single-item paper questionnaire, the instructions included a diagram of the medial view of a leg with the area between the ankle and the groin circled. The patient was instructed to choose 1 of 5 response options that best described the appearance of the visible varicose veins of the leg that was treated in the study. The patient was instructed not to consider the appearance of the leg outside the circled area or of any spider veins. Possible responses ranged from "Not at all noticeable" (a score of 0) to "Extremely noticeable" (a score of 4).

  2. Change From Baseline at 8 Weeks Post Treatment in IPR-V3 Score- Physician Photographic Review of Appearance [ Time Frame: 8 weeks post treatment ]
    The Independent Photography Review - Visible Varicose Veins (IPR-V3) instrument is a 5-point scale used to assess the appearance of a patient's visible varicose veins. At baseline and Week 8, standardized digital photographs were taken of the medial view of the patient's target leg, from groin to ankle. An independent photography review panel, consisting of 3 trained, blinded clinicians evaluated the appearance of the patient's visible varicose veins using the IPR-V3 instrument's 5-point scale (where 0=none to 4=very severe visible varicose veins).

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   18 Years to 75 Years   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Incompetence of SFJ associated with incompetence of the GSV or other major accessory vein
  • Ability to comprehend and sign an informed consent document and complete study questionnaires in English
  • Ability to record symptoms in accordance with the protocol
  • Symptomatic varicose veins
  • Visible varicose veins

Exclusion Criteria:

  • Patients who only have telangiectatic or reticular veins (Clinical Finding C1, as assessed by CEAP (clinical, etiologic, anatomic, and pathophysiologic) Classification of Venous Disorders).
  • Leg obesity impairing the ability to access the vein to be treated and/or to apply postprocedure compression bandaging and stockings
  • Ultrasonographic or other evidence of current or previous deep vein thrombosis or occlusion
  • Deep vein reflux unless clinically insignificant in comparison to superficial reflux
  • Peripheral arterial disease precluding the wearing of post-procedure compression bandaging and stockings
  • Reduced mobility
  • Major surgery, prolonged hospitalization or pregnancy within 3 months of screening
  • Major co-existing disease (e.g. malignancy; pulmonary disease; renal or hepatic insufficiency; serious skin disease/condition that may compromise the ability of the patient to comply with the compression protocol, etc.)
  • Known allergic response to polidocanol or heparin, including history of heparin-induced thrombocytopenia, and/or multiple allergic reactions
  • Current alcohol or drug abuse
  • Pregnant or lactating women
  • Women of childbearing potential not using effective contraception
  • History of DVT, pulmonary embolism or stroke

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01072877

Layout table for location information
United States, California
Laguna Hills, California, United States, 92653
San Diego, California, United States
United States, District of Columbia
Washington, District of Columbia, United States, 20007
United States, Florida
Aventura, Florida, United States, 33180
Bradenton, Florida, United States, 34209
United States, Illinois
Oakbrook Terrace, Illinois, United States, 60181
United States, Michigan
Ann Arbor, Michigan, United States, 48109
Kalamazoo, Michigan, United States, 49009
United States, New York
Hartsdale, New York, United States, 10530
New York, New York, United States, 10016
North Tonawanda, New York, United States, 14120
Stony Brook, New York, United States, 10530
United States, North Carolina
Charlotte, North Carolina, United States, 28207
Durham, North Carolina, United States, 27705
Winston-Salem, North Carolina, United States, 27157
United States, Ohio
Toledo, Ohio, United States, 43606
United States, Oregon
Bend, Oregon, United States, 97701
United States, Tennessee
Clarksville, Tennessee, United States, 37040
United States, Washington
Kirkland, Washington, United States, 98034
Spokane, Washington, United States, 99204
Sponsors and Collaborators
Boston Scientific Corporation
Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):
Layout table for additonal information
Responsible Party: Boston Scientific Corporation
ClinicalTrials.gov Identifier: NCT01072877    
Other Study ID Numbers: VAP.VV015
First Posted: February 22, 2010    Key Record Dates
Results First Posted: May 16, 2014
Last Update Posted: April 21, 2021
Last Verified: April 2021
Keywords provided by Boston Scientific Corporation:
Varicose Veins
Additional relevant MeSH terms:
Layout table for MeSH terms
Varicose Veins
Vascular Diseases
Cardiovascular Diseases
Sclerosing Solutions
Pharmaceutical Solutions